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Abstract 
Background & Aims: Helicobacter pylori infection is a risk factor for gastric cancer. To explore 
the genetic basis of gastric cancer that develops in inflamed gastric mucosa, we investigated 
genetic aberrations that latently accumulate in non-tumorous gastric epithelium with H pylori 
infection. 
Methods: We performed whole exome sequencing of gastric tumors, non-cancerous tissues with 
gastritis, and peripheral lymphocytes from 5 patients. We performed additional deep-sequencing 
analyses of selected tumor-related genes using 34 gastritis mucosal samples from patients with or 
without gastric cancer. We also performed deep sequencing analyses of gastric mucosal tissues 
from mice that express transgenic human TP53 and constitutively express activation-induced 
cytidine deaminase (AICDA or AID) (Hupki/AID-Tg mice).  
Results: Whole-exome sequencing revealed that somatic mutations accumulated in various 
genes in inflamed gastric tissues. Additional deep sequencing analyses of tissues from regions of 
gastritis confirmed non-synonymous low-abundance mutations in TP53 in 15 cases (44.1%) and 
ARID1A in 5 cases (14.7%). The mutations that accumulated in gastric mucosal tissues with H 
pylori-induced gastritis, as well as gastric tumors, were predominantly C:G>T:A transitions in 
GpCpX motifs²a marker of cytidine deamination induced by AID. Constitutive expression of 
AID in the gastric mucosa of mice led to mutations in the human TP53, at amino acid coding 
positions identical to those detected in human gastric cancers.  
Conclusions: Studies of gastric tumors and tissues from humans and mice indicate that somatic 
mutations accumulate in various genes in gastric mucosal tissues with H pylori infection. 
Increased cytidine deaminase activity in these tissues appears to promote the accumulation of 
these mutations and might promote gastric carcinogenesis in patients with H pylori infection. 
Keywords: stomach cancer; somatic hypermutation; pathogenesis; bacteria
Introduction 
The recent introduction of deep sequencing technology, capable of detecting sequences of 
hundreds of thousands of individual molecules, is rapidly changing the landscape of cancer 
genome research. Comprehensive genome analyses using the deep sequencing technique have 
clarified that each tumor cell has numerous nucleotide alterations1. Among the genetic 
aberrations, driver mutations are thought to contribute to tumorigenesis by conferring a selective 
advantage to the cell. On the other hand, passenger mutations are defined as those that do not 
alter fitness but occur in a cell that coincidently, or subsequently, acquired a driver mutation2. 
Recent reports demonstrated that human gastric cancer has approximately 66 to 212 mutations in 
coding regions, and only a few of them are considered driver mutations3-6. Among them, 
mutations in the tumor suppressor TP53 gene are the most common driver mutations in human 
gastric cancer tissues. A second common putative driver mutation was determined in the 
chromatin remodeling complexes gene, ARID1A3. It remains unclear, however, when and how 
those driver mutations emerge in the gastric epithelium during tumorigenesis. 
Epidemiologic studies revealed that patients with Helicobacter pylori (H pylori) infection 
have a significantly increased risk of gastric cancer compared to H pylori-negative individuals7, 8. 
The more prevalent form of gastric adenocarcinoma frequently progresses through a series of 
histologic steps that are initiated by chronic gastritis, which then leads to atrophic gastritis and 
intestinal metaplasia, and finally to dysplasia and adenocarcinoma in individuals with H pylori 
infection9. Multicentric tumor development characterized in H pylori-associated gastric cancer10 
suggests that the H pylori-infected stomach could include epithelial cells and/or intestinal 
metaplasia with genetic damage that possess high susceptibility to tumor development11. 
Consistent with these findings, animal experiments using Big Blue mice revealed a high 
mutation frequency in the H pylori-infected gastric mucosa12, which are increased in 
Helicobacter-infected Big Blue-p53 hemizygous mice13. The precise mechanism for the 
emergence of genetic alterations in H pylori-infected gastric mucosa, however, has not been 
elucidated. We recently demonstrated that H pylori infection and the resultant chronic 
inflammation with mononuclear cell infiltration induces genetic alterations, including somatic 
mutations and chromosomal aberrations, in gastric epithelial cells through the expression of a 
DNA-mutator enzyme, activation-induced cytidine deaminase (AID)14-17. In vitro studies 
revealed that H pylori infection elicited the ectopic expression of AID in association with a high 
mutation frequency of the TP53 genome sequences14. To date, however, there has not been 
enough evidence showing that AID expression in gastric mucosa in vivo causes the accumulation 
of driver mutations in the human TP53 sequences required for malignant transformation. 
To clarify the mechanisms underlying the contribution of inflammation to carcinogenesis, it is 
important to identify the genetic alterations that occur in the inflamed epithelium before the onset 
of tumorigenesis. The main obstacle to detecting latently accumulated genetic alterations in 
non-tumorous inflamed tissue is the diversity and low frequency of the mutated genes18. In the 
present study, to unveil the landscape of accumulated genetic aberrations in chronically inflamed 
gastric epithelium, we performed whole exome sequencing and additional deep sequencing of 
the inflamed gastric mucosa with chronic H pylori infection. Furthermore, to confirm whether 
constitutive AID expression in vivo contributes to the emergence of the TP53 mutations, we 
determined the mutation profile of the TP53 gene in the AID-expressing gastric mucosa of the 
human TP53 knock-in mouse model. 
Materials and methods 
Whole exome capture and massively-parallel sequencing. 
Massively-parallel sequencing was performed as described previously19, 20. Fragmented DNA 
(>5 µg) was used to prepare each DNA sequencing library. The DNA libraries were prepared 
according to the instructions provided with the Illumina Preparation Kit (Illumina, San Diego, 
CA). Whole exome sequence capture was then performed using SeqCap EZ Human Exome 
Library v2.0 (Roche, Madison, WI) according to the manufacturer's instructions. Cluster 
generation was performed on the Illumina cluster station using their TruSeq PE Cluster Kit v5. 
Paired-end sequencing for 2 × 76 base pair (bp) reads was performed on the Illumina Genome 
Analyzer IIx using their SBS Kits v5. Data collection and base-calling were performed using 
SCS v2.9/RTA 1.9 and resultant data files were converted to the FASTQ format.  
Sequencing data were analyzed with NextGENe 2nd Generation Sequence Analysis Software 
v2.2.0 (SoftGenetics, State College, PA). We identified somatic mutations by the strict variant 
filtering process (Supplementary Figure 1 and Supplementary materials and methods). To 
validate somatic mutations, we performed PCR-based deep-sequencing using a different 
deep-sequencing platform (the GS Junior System, Roche) on the non-silent mutations detected 
by whole exome sequencing, according to the validation protocol reported in the recent study21. 
We estimated that the reliabilities of whole exome sequencing were 88.6% for somatic mutations 
detected in the tumor tissues and 86.4% for somatic mutations detected in the non-tumor tissues 
(data not shown). Primer sequences are shown in Supplementary Table 1.  
Deep sequencing on selected genes. 
The mutational status of TP53, ARID1A, MLL2, SUV39H1, CTNNB1, PIK3CA, and TP53 
cDNA was investigated by high-coverage sequencing analyses. Target regions were designed 
within the range from 330 to 520 bp. The primer sequences are described in Supplementary 
Table 2. Each region was PCR-amplified with Phusion High-Fidelity PCR Enzyme (FINZYMES, 
Espoo, Finland), purified by gel-extraction methods. Five hundred nanograms of each sample 
was dA-tailed and ligated with adaptors containing tag sequences, followed by emulsion PCR 
and sequencing using the GS Junior System (Roche) according to the manufacturer's protocol.  
Deep sequencing data were analyzed with NextGENe software. We identified low-abundance 
somatic mutations by the strict variant filtering process (Supplementary Figure 2 and 
Supplementary materials and methods). Candidate low-abundance mutations were validated by 
repeated deep sequencing using independent amplicons derived from the same samples. 
 
Tissue specimens and DNA extraction. 
Animal Experiments. 
Whole exome sequencing analysis and variant filtering. 
Deep sequencing analysis and variant filtering. 
Functional prediction analysis and pathway analysis. 
Statistical analysis. 
These procedures and information are described in the Supplementary Materials and Methods. 
Results 
Landscape of genetic alterations that accumulated in H pylori-associated gastric cancers. 
To overview the landscape of genetic alterations that accumulated in both gastric cancer and 
the adjacent background inflamed mucosa with H pylori infection, we performed whole exome 
sequencing of 5 matched pairs of gastric cancer and non-cancerous gastritis tissues in patients 
with H pylori infection. To subtract the normal variants of each individual from the somatic 
mutations, we also determined the whole exome sequences of the matched peripheral 
lymphocytes in each patient. Microsatellite analysis revealed that one gastric cancer had 
microsatellite instability (MSI) and the remaining four tumors had the characteristics of 
microsatellite stability (MSS). All background gastric mucosa had the features of chronic 
gastritis with mucosal atrophy and intestinal metaplasia and none of the gastric specimens 
included dysplastic lesions (Supplementary Table 3).  
We targeted the whole exons of approximately 20,000 genes, sequenced 3.33Gb on average 
for each sample, and achieved 41.2-fold coverage per samples as the mean coverage of each base 
in the target regions (Supplementary Table 4). According to the variant filtering process 
(Supplementary Figure 1), we identified single nucleotide variants (SNVs), short insertions and 
deletions (indels) in cancer tissues as well as in the non-cancerous gastritis mucosa.  
We identified 892 somatic mutations in 793 genes in the 5 gastric cancer tissues. The 
identified mutations included 654 non-silent mutations (552 missense, 25 nonsense, 1 stop codon 
loss, 11 essential splice site mutations, and 65 indels) and 238 synonymous mutations 
(Supplementary Tables 5, 6). The number of non-silent mutations in the MSI gastric cancer 
sample was significantly higher than those of any of the MSS tumor samples (Figure 1A). In 
addition, the MSI tumor also had a large number of indels, while the MSS tumors had only a few 
indels (Figure 1C, Supplementary Table 5). Furthermore, the mutation frequency at each 
nucleotide position in the MSI tumor tended to be higher than those in the MSS tumors (Figure 
1B). These findings indicated that MSI gastric cancers have enhanced genetic aberrations 
compared with MSS tumors. 
 
Mutation profiles of MSS and MSI gastric cancer tissues. 
Among the mutated genes identified, 26 genes were recurrently mutated as non-synonymous 
mutations or indels in two or more gastric cancers (Table 1). These genes included TP53 
(mutated in 3 of 5 cases), and ARID1A (mutated in 2 of 5 cases), mutations of which were 
mutually exclusive3, 4. All of the TP53 mutations were present as a type of nucleotide substitution 
in three MSS tumor tissues, whereas the ARID1A mutations were detected as deletions in the one 
remaining MSS and in one MSI gastric cancer. Pathway analyses in the five gastric cancers 
revealed that cell adhesion4 was the most significantly enriched biological process, followed by 
metabolic processes, endocytosis and extracellular structure organization (Supplementary Table 
7).  
Recent studies showed that the pattern of nucleotide alterations could provide a clue to 
determine the molecular process underlying mutation occurrence22-27. We first confirmed that 
over half of the SNVs that accumulated in the exome sequences of gastric cancer tissues were 
enriched with a C:G>T:A transition (p<0.01 by ANOVA, Figure 1C). The prevalence of these 
C:G>T:A transitions in the MSI gastric cancer was substantially higher than that in the MSS 
tumors (65.1% vs. 48.9%, respectively). These mutational signatures suggested that cytidine to 
uracil deamination is deeply implicated in the mutational process underlying H pylori-associated 
gastric carcinogenesis. Among the cytidine deaminase family proteins, AID exhibits a strong 
SUHIHUHQFH IRU GHDPLQDWLQJ & UHVLGXHV IODQNHG E\ D ¶-purine (G or A)22, 28, 29. In contrast, 
APOBEC3 family enzymes and APOBEC1 favor C residuHVIODQNHGE\¶-T30, 31. Therefore, we 
further evaluated the sequence characteristics flanking the mutated C residues in tumor tissues. 
Consistent with the previous report5, we found that the GpCpX (C is the mutated nucleotide and 
X is any base, GpCpA: 23.9%, GpCpC: 24.3%, GpCpG: 38.4%, GpCpT: 13.4%) pattern 
dominated across all of the tissues examined (p<0.01 by ANOVA), followed by CpCpX and 
ApCpX (Figure 1D), suggesting that deamination achieved by AID activity is likely to be 
involved in the mutational signature of H pylori-associated gastric cancers. 
 
Overview of genetic alterations that accumulated in non-cancerous gastritis mucosa with H 
pylori infection. 
Whole exome sequencing clarified that various mutations were also present in the 
non-cancerous H pylori-infected gastritis mucosa. All of the mutations detected in the 
non-tumorous gastric mucosa were SNVs and no indels were observed in any of the 
non-tumorous gastritis tissues. The mean number of mutated genes in the non-tumorous tissues 
was 28.4 per sample, which was lower than that in the matched tumor tissues of all 5 patients 
(Supplementary Tables 5, 8). In addition, the mutation frequency at each nucleotide position 
represented less than 20% of the total reads of the majority of the altered genes in non-tumorous 
gastric mucosa (Figure 1B), indicating that the mutation frequency at each nucleotide position 
tended to be lower in the non-cancerous tissues than in the cancer tissues. The total number of 
mutated genes and mutant allele frequencies in the non-tumorous tissues did not significantly 
differ between the patient with MSI and those with MSS cancers (Figure 1A, 1B, Supplementary 
Table 5). 
Among the 142 mutations identified in the 5 non-tumorous gastritis tissues, 91 mutations 
(64.1%) were non-silent. Sorting Intolerant From Tolerant (SIFT) functional impact predictions32 
revealed that the mean percentages of somatLF PXWDWLRQV SUHGLFWHG WR EH ³GDPDJLQJ´ RU
frame-shift, nonsense and splice site mutations in non-tumorous gastritis and cancer tissues were 
29.6% and 44.7%, respectively (p<0.01 by Ȥ2 test), suggesting that the SNVs that accumulated in 
the non-tumorous tiVVXHV PRUH IUHTXHQWO\ LQFOXGHG ³SDVVHQJHU´ PXWDWLRQV ZLWK OHVV IXQFWLRQDO
significance than those in the tumor tissues (data not shown). Pathway analyses revealed that 
transcription-related genes, such as MLL2 and SUV39H1 that are involved in chromatin or 
histone modification, were frequently altered in non-tumorous gastritis tissues (Supplementary 
Table 9). Whole exome sequencing also revealed 25 genes that were commonly mutated in both 
the tumor and the matched background gastritis mucosa of the same patients (Supplementary 
Tables 10 and 11). Among them, 16 genes acquired non-synonymous mutations and Sanger 
sequencing confirmed that those SNVs were not detected in the matched control lymphocytes, 
while the biological role of these mutated genes remains unclear. 
 
Establishment of deep sequencing platform for detecting low-abundance mutations in 
tumor-related genes. 
Whole exome sequencing clarified that somatic mutations accumulated in various genes in H 
pylori-infected gastritis mucosa, while the majority of the mutated genes detected were supposed 
WREH³SDVVHQJHU´ mutations. Those findings prompted us to examine whether somatic mutations 
latently accumulate LQ ³GULYHU´ JHQHV WKDW FRXOG FRQWULEXWH WR JDVWULF WXPRULJHQHVLV DQG WKXV
deep sequencing analysis of the selected amplicons of tumor-related genes were applied to the 
non-tumorous gastric mucosa and the matched peripheral lymphocytes from H pylori (+) patients 
with and without gastric cancers.  
First, we conducted control experiments to validate the efficacy and error rates in deep 
sequencing using a plasmid encoding the TP53 cDNA sequence as a template. The deep 
sequencing platform provided us the TP53 sequences derived from the plasmids with a mean 
coverage of 4024 at each nucleotide site and the error rate per nucleotide position was below 
0.07%. To estimate the accuracy of detecting nucleotide alterations using reads filtered by mean 
base quality and mapping quality, we introduced expression plasmids with a single point 
mutation within this wild-type sequence with a ratio of 1%(1:100), 0.1%(1:1000), or 
0.01%(1:10000). Duplicate control experiments revealed that mutations present at an input ratio 
of 0.1% were detected ranging between 0.11% and 0.12% (Supplementary Table 12). Based on 
these results, the limit of mutant allele frequencies detectable by this deep sequencing was 
considered to be more than 0.1% of the total reads. Finally, to exclude the errors during the 
sequencing process, repeated experiments were performed and we determined that nucleotide 
alterations validated by at least more than two different deep sequencings were low-abundance 
somatic mutations.  
 
Somatic mutations accumulated in tumor-related genes in H pylori infection-related 
gastritis mucosa. 
We performed deep sequencing on the selected amplicons of tumor-related genes in H 
pylori-related gastritis mucosa in 28 patients with gastric cancer and 6 patients without gastric 
cancer (Supplementary Table 13). Consistent with the previous studies3, 4, our whole exome 
sequencing on 5 tumor tissues identified that TP53 and ARID1A were frequently mutated in 
gastric cancer tissues. In addition, the previous studies clarified that CTNNB1 and PIK3CA are 
also frequently mutated in gastric cancer tissues3, 4. Based on those findings, we selected these 
four genes (TP53, ARID1A, CTNNB1 and PIK3CA) for further deep-sequencing analyses. In 
addition, we targeted MLL2 and SUV39H1, which were identified by current whole exome 
sequencing in non-cancerous gastritis tissues. The mean coverage ranged from 2319 to 12,934 
fold at each targeted gene.  
We first verified that no nucleotide alterations were detected in normal gastric mucosa without 
H pylori infection or any lymphocytes of the enrolled patients. Deep sequencing on 34 gastritis 
mucosa revealed that a lot of non-synonymous mutations were present at a very low frequency 
(0.11-1.12%) in various genes (p<0.05 by Ȥ2 test). We validated the results by repeated deep 
sequencings and confirmed that 83.7% of the nucleotide changes detected by the initial analyses 
were also detected by the independent deep sequencing analyses (Supplementary Table 14). In 
the gastritis mucosa of 28 patients with gastric cancer, we identified non-synonymous 
low-abundance mutations in 13 nucleotide positions of TP53 in 11 cases, 6 positions of ARID1A 
in 4 cases, and 3 positions of MLL2 in 2 cases, while no mutations were detected in CTNNB1, 
PIK3CA, and SUV39H1 (Table 2). In addition, in the gastritis mucosa of 6 patients without 
gastric cancer, non-synonymous low-abundance mutations were detected in 6 positions of TP53 
in 4 cases and in 1 position of ARID1A in 1 case (Table 3).  
Mutational status in non-cancerous gastritis mucosa was not significantly associated with the 
stage, differentiation, MSI status, or mutational status of the corresponding gastric cancers (data 
not shown). Regarding the mutation signature in non-tumorous gastritis mucosa, deaminating C 
UHVLGXHVIODQNHGE\D¶-purine (G or A) were strongly preferred, similar to that in gastric cancer 
tissues. Indeed, 15 of 19 (78.9%) low-abundance TP53 mutations in H pylori-related gastritis 
mucosa with or without gastric cancer were C:G>T:A transitions (p<0.01 by Ȥ2 test) and all of 
these transitions accumulated in the context of GpCpX (Figure 2A). Numbers of the mutated 
TP53 nucleotide positions observed in the gastritis mucosa were identical to those that 
accumulated in human gastric cancer tissues (IARC TP53 database, R16, November 2012, 
http://p53.iarc.fr/), including codons 245 and 273 (Figure 2B, 2C).  
 
Mutation signature induced by AID activity that accumulated in human TP53 genes in vivo.   
The mutation spectrum determined in the TP53 sequences supported the possibility that 
AID-mediated deamination activity is deeply involved in the induction of driver mutations in 
tumor-related genes during human gastric carcinogenesis. To gain further insight into the role of 
AID in the emergence of somatic mutations in vivo, we determined the nucleotide sequences of 
the human TP53 genes in the gastric mucosa of the human TP53 knock-in (Hupki) mice33 after 
crossing them with AID transgenic (Tg) mice using deep sequencing analysis. Although the 
mean coverage reached 6434-fold, only one low-abundance mutation was detected in the human 
TP53 sequences from the gastric mucosa of 6 control Hupki mice with any type of codon 72 
polymorphic variant (codon72 Arg/Arg, Pro/Pro and Arg/Pro) (Table 4). In contrast, 
low-abundance mutations accumulated in the human TP53 gene sequences in the gastric mucosa 
of 6 of 7 (85.7%) Hupki/AID-Tg mice (p=0.053 by Ȥ2 test, Table 4). 8 of 9 (88.9%) genetic 
alterations determined in the gastric mucosa of 6 Hupki/AID-Tg mice were C:G>T:A transitions 
at the GpCpX motif (p<0.01 by Ȥ2 test). Moreover, numbers of the low-abundance TP53 
mutations were identical to the amino acid positions altered in human gastric cancer tissues34, 35 
(Figure 2D). These findings provide evidence that the AID-mediated cytidine deamination could 
be deeply involved in the nucleotide alterations of the human TP53 gene that accumulate in the 
gastric mucosa during gastric tumorigenesis.  
Discussion 
Chronic inflammation plays a critical role as a background of cancer development16, 36, 37. 
Therefore, it is reasonable to assume that stepwise accumulation of genetic alterations that 
contribute to tumorigenesis occurs in chronically inflamed epithelial cells. Consistently, several 
studies have reported that genetic aberrations are frequently detected in non-tumorous inflamed 
epithelial tissues where the risk of cancer development is remarkably high38-40. For example, 
TP53 mutations are detected in the inflamed mucosa of the colonic epithelium of patients with 
inflammatory bowel disease41, 42. A recent sequencing study on Barrett¶s esophagus revealed 
that the mutational profiles of Barrett¶s esophagus and esophageal adenocarcinoma are 
remarkably similar, suggesting that genetic alterations in the metaplasia±carcinoma sequence of 
Barrett¶s esophagus occur much earlier than the histologic changes of frank dysplasia40. In the 
present study, using a whole exome sequencing technique, we demonstrated that somatic 
mutations accumulated not only in tumors but also in the non-tumorous inflamed gastric mucosa 
infected with H pylori. 
Regarding the cancer tissues, whole exome sequencing determined a remarkable difference in 
the mutation signature between MSI and MSS tumors. Namely, MSS tumors possessed a 
relatively lower number of total mutations, including SNVs and indels, compared with the MSI 
tumor. Indeed, the 4 MSS gastric cancer samples had an average of 56 non-silent somatic 
mutations with few indels, while the MSI gastric cancer sample had 427 non-silent somatic 
mutations including a large number of indels, consistent with the previous reports3, 6. Moreover, 
the frequency of mutations at each nucleotide position in the MSS cancers tended to be lower 
than that in the MSI tumor. Notably, the mutation signature in non-tumorous background gastric 
mucosa did not differ significantly between patients with MSS and MSI tumors. These findings 
suggest that the outstanding features of genetic instability characterized as MSS and MSI 
phenotypes were not evident in the premalignant condition of gastric mucosa underlying H 
pylori infection and resultant chronic inflammation, and would only become evident in the tumor 
cells after malignant transformation. Since the allelic fraction is highly dependent on the cell 
purity in the tissue samples, we should pay attention to the possibility that the tumor or epithelial 
cell purity could cause differences in the mutation frequencies in each tissue specimen analyzed. 
Whole exome sequencing also clarified that the somatic mutations in various genes were 
latently accumulated in the non-tumorous gastritis mucosa of patients with H pylori infection. It 
is notable that the total number of mutated genes of the non-tumorous gastric mucosa was 
smaller than that of the matched tumor tissues and the majority of the mutations detected in 
gastritis mucosa were predicted to have no influence on cell behavior, suggesting that most of the 
mutations in gastritis mucosa were passenger mutations. To unveil whether mutations of driver 
genes were present in gastritis mucosa, we conducted deep sequencing of the selected target 
genes on H pylori (+) gastric epithelium. The sensitivity of ultra-deep sequencing analysis is 
primarily limited by errors introduced during any process of the sample preparation and the 
sequencing reaction, including PCR amplification, cluster amplification, cycle sequencing, 
image analysis, and others; thus, it is a challenge to distinguish rare mutations from sequencing 
artifacts18. In the present study, we optimized the deep sequencing by defining a strict filter 
setting and confirmed that no nucleotide alterations over the cut-off were detected in the control 
lymphocytes or in normal gastric mucosa. Furthermore, we validated the results by repeating the 
deep sequencing using independent amplicons derived from the same patients, although errors 
cannot completely be ruled out. Through these strict validation processes, we reproducibly 
detected low-abundance somatic mutations in non-tumorous gastric mucosa with H pylori 
infection. Interestingly, TP53 was the most frequently mutated gene in gastritis mucosa among 
the six tumor-related genes analyzed. Strikingly, numbers of the mutated TP53 nucleotide 
positions observed in gastritis mucosa were located at the nucleotide positions of the mutations 
that accumulated in human gastric cancer tissues. It is not known whether the low-abundance 
TP53 mutations latently present in gastric mucosa with H pylori infection derive from the 
clinically-undetectable small tumor cells or untransformed epithelial cells under premalignant 
conditions. It is reasonable to assume, however, that the low-abundance TP53 mutations in the 
background gastric mucosa with H pylori infection could be the source of gastric cancer cells. 
Recent studies showed that the mutation signature that accumulates in tumor tissues provides 
the clue to identifying the cause of genetic alterations during tumor development22-27, 43. It was 
shown that C:G>T:A transitions at XpCpG trinucleotides were especially prominent in many 
cancer types27, 44. Among the C:G>T:A transitions, the footprint of AID is characterized by 
C:G>T:A alterations that occur in GpCpX or ApCpX sequences22, 28, 29, 45-47. In the current study, 
we found that the frequency of C:G>T:A transitions was the highest pattern of SNVs 
accumulated in the whole exome sequences of all five cancer tissues examined. Interestingly, the 
C:G>T:A mutations in gastric cancer genomes predominantly accumulated in the context of 
GpCpX or ApCpX, suggesting the involvement of AID-mediated cytidine deamination in the 
induction of somatic mutations during gastric carcinogenesis. 
We previously revealed a causal relationship between mutagenic AID activity and the 
accumulation of TP53 mutations during the development of human gastric cancers14. The present 
findings showing the detection of low-abundance TP53 mutations with the typical footprint of 
AID activity in inflamed human gastric mucosa further support the putative role of AID in the 
generation of genetic alterations in an inflammatory microenvironment of gastric mucosa with H 
pylori infection. The differences in p53 gene sequences between humans and mice, however, 
made it difficult to confirm whether constitutive AID expression in gastric mucosa in vivo 
contributes to the emergence of TP53 mutations that are identical to those observed in human 
gastritis and gastric cancer tissues. It is well established that Hupki mice, in which exons 4-9 of 
human TP53 were knocked in the corresponding mouse exons, are useful models for studying 
human TP53 mutagenesis33, 48, 49. Therefore, in this study we performed deep sequencing 
analyses on human TP53 gene of gastric mucosa derived from Hupki mice with, and without, 
constitutive AID expression. AID expression in gastric mucosa resulted in the accumulation of 
low-abundance human TP53 mutations with the typical signature of AID-mediated cytidine 
deamination. Strikingly, numbers of the amino acid changes determined in AID-expressing 
gastric mucosa of Hupki mice accumulated at positions identical to those altered in human 
gastric cancers. Taken together, these findings strongly suggest that constitutive AID expression 
in gastric epithelium plays a critical role in the accumulation of human TP53 mutations during 
the development of gastric cancers (Figure 3). To clarify the role of AID in the accumulation of 
somatic mutations and tumorigenesis in the stomach in vivo, further analyses of aberrant AID 
expression and resultant Trp53 mutations in gastric inflamed mucosa are required using 
previously established mouse models with inflammation-associated gastric carcinogenesis50-52. 
In summary, we demonstrated that various mutations were latently accumulated in the gastric 
mucosa in patients with H pylori infection. The combination of whole exome sequencing with 
deep sequencing enabled us to unveil the landscape of mutations that latently accumulated in 
non-tumorous gastritis mucosa. Interestingly, the mutation signature not only in gastric cancer 
genomes but also in gastritis mucosa suggested that AID-mediated deamination events were 
predominant during the process of gastric carcinogenesis. In particularly, a causal relationship 
between AID activity and the accumulation of TP53 mutations was also validated by in vivo 
models. It is expected that uncovering the landscape of genetic alterations in gastritis mucosa 
will contribute to clarifying the mechanism of gastric cancer development. 
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Figure legends 
Figure 1. Somatic mutations in tumor and non-tumorous gastric tissues determined by whole 
exome sequencing.  
(A) Number of non-synonymous and synonymous mutations in each sample. C001-C004 had 
gastric cancers with MSS features, and C005 had gastric cancer with MSI features. 
(B) Distribution of the mutation frequency determined in each sample (at a frequency of 10% 
of reads). The proportions of mutations whose frequencies were less than 20% of the total reads 
significantly differed between cancer tissues and non-cancerous tissues in C001, C003, C004, 
and C005 (p<0.01 by Ȥ2 test). 
(C) Mutation signature determined in one MSI and four MSS gastric cancer tissues. C:G>T:A 
transitions in MSS cancer samples were significantly enriched (p<0.01 by ANOVA).  
(D) Sequence context of the C:G>T:A transitions in one MSI and four MSS gastric cancer 
tissues. GpCpX patterns in MSS cancer samples were significant enriched (p<0.01 by ANOVA). 
*MSI status was determined from gastric cancer tissue. 
**T: tumor, NT: non-tumorous gastritis mucosa 
 
Figure 2. Low-abundance mutations accumulated in TP53 genes in human gastritis mucosa and 
human TP53-knock-in mice stomach.  
(A) Mutation signature of 19 low-abundance TP53 mutations in H. pylori-related gastritis 
mucosa of 34 patients with or without gastric cancer determined by deep sequencing. These 
low-abundance TP53 mutations included 15 C:G>T:A transitions, 3 T:A>C:G transitions and 1 
C:G>A:T transversion. C:G>T:A transitions were significantly enriched (p<0.01 by ANOVA). 
(B) Distribution of low-abundance TP53 mutations in human gastritis mucosa of 34 patients with 
or without gastric cancer identified by deep sequencing. 
(C) Distribution of TP53 mutations in human gastric cancers obtained from IARC TP53 database 
(http://p53.iarc.fr/). 
(D) Distribution of low-abundance TP53 mutations in gastric mucosa of seven 12-month-old 
Hupki/AID-Tg mice. 
 
Figure 3. Schematic summary for AID-mediated TP53 mutations and gastric cancer 
development. 
H pylori infection and inflammatory signals such as TNF-Į LQGXFH DEHUUDQW H[SUHVVLRQ RI a 
DNA-mutator enzyme, AID, in gastric epithelial cells. AID-mediated mutagenesis of driver 
genes including TP53 could contribute to gastric carcinogenesis.  
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Table 1. List of 26 genes recurrently mutated in two or more tumor tissues of 5 gastric cancer 
patients. 
 
Gene symbol Gene name 
Gene 
size 
(bp) 
# of 
mutated 
samples 
# of 
mutations 
  
 
  
OBSCN obscurin, cytoskeletal calmodulin and titin-interacting 
RhoGEF  
23,907 3 4 
TP53 tumor protein p53 1,182 3 3 
MUC17 mucin 17, cell surface associated 13,482 2 2 
HRNR hornerin  8,553 2 3 
FLG filaggrin  12,186 2 2 
PCDHB5 protocadherin beta 5 2,388 2 3 
PRB1 proline-rich protein BstNI subfamily 1 996 2 2 
RORB RAR-related orphan receptor B 1,380 2 2 
SLC35G6 solute carrier family 35, member G6 1,017 2 2 
ARID1A AT rich interactive domain 1A (SWI-like) 6,858 2 2 
CACNA1B calcium channel, voltage-dependent, N type, alpha 1B 
subunit 
7,020 2 2 
CD163 CD163 molecule 3,471 2 2 
CEP164 centrosomal protein 164kDa 4,383 2 2 
CNGB1 cyclic nucleotide gated channel beta 1 900 2 2 
COL5A1 collagen, type V, alpha 1 5,517 2 2 
CYP2A6 cytochrome P450, family 2, subfamily A, polypeptide 
6 
1,485 2 2 
FCGBP Fc fragment of IgG binding protein 16,218 2 2 
GPC6 glypican 6 1,668 2 2 
HCN2 hyperpolarization activated cyclic nucleotide-gated 
potassium channel 2 
2,670 2 2 
PCDHA3 protocadherin alpha 3 2,853 2 2 
RABGGTA Rab geranylgeranyltransferase, alpha subunit 1,704 2 2 
RAD54L2 RAD54-like 2 (S. cerevisiae) 4,404 2 2 
ROPN1B rhophilin associated tail protein 1B 639 2 2 
SPDYE5 speedy homolog E5 (Xenopus laevis) 1,014 2 2 
SUPT6H suppressor of Ty 6 homolog (S. cerevisiae) 5,181 2 2 
TUBGCP2 tubulin, gamma complex associated protein 2 2,793 2 2 
     
 
Table 2. Low-abundance mutations in H pylori-related gastritis mucosa of patients with gastric cancer detected by 
deep sequencing. 
 
Case* TP53 DNA binding domain 
ARID1A 
exon20 
MLL2 
SET domain 
SUV39H1 
SET domain 
CTNNB1 
exon3 
PIK3CA 
exon21 
C001 None None None None None None 
C002 c.365T>C p.V122A c.734G>A p.G245D None None None None None 
C003 None c.5763C>T p.T1921T None None None None 
C004 c.734G>A G245D None None None None None 
C005 None None None None None None 
C006 None c.5920C>T p.Q1974X 
c.6001A>G p.M2001V None None None None 
C007 c.712T>C p.C238R None None None None None 
C008 None None c.16373A>G p.E5458G 
c.16438A>G p.N5480D None None None 
C009 c.734G>A p.G245D None None None None None 
C010 None None None None None None 
C011 c.734G>A p.G245D None None None None None 
C012 c.329G>T p.R110L c.5983C>T p.P1995S None None None None 
C013 c.503A>G p.H168R 
c.827C>T p.A276V None None None None None 
C014 None None None None None None 
C015 None c.5307A>G p.L1769L 
c.5607G>A p.R1869R None None None None 
C016 None None c.16428C>T p.S5476S None c.99T>C p.S33S None 
C017 c.734G>A p.G245D c.5406G>A p.E1802E None None None None 
C018 None None None None None None 
C019 None None None None None None 
C020 None None c.16379T>A p.V5460E None None None 
C021 None None None None None None 
C022 None None None None None None 
C023 c.817C>T p.R273C None None None None None 
C024 c.827C>T p.A276V c.5239C>T p.P1747S 
c.5503C>T p.Q1835X None None None None 
C025 None c.5482T>C p.S1828P None None None None 
C026 c.734G>A p.G245D None None None None None 
C027 None None None None None None 
C028 None None None None None None 
All low-abundance mutations in this table were validated by repeated deep sequencing. 
Low-abundance mutations written in bold letters are non-synonymous, and those written in small letters are synonymous 
*C001-C028 are H pylori-related gastritis patients with gastric cancer.  
 
Table 3. Low-abundance mutations in H pylori-related gastritis mucosa of patients without gastric cancer and 
normal gastric mucosa detected by deep sequencing. 
 
Case* TP53 DNA binding domain 
ARID1A 
exon20 
MLL2 
SET domain 
SUV39H1 
SET domain 
CTNNB1 
exon3 
PIK3CA 
exon21 
A029 c.734G>A p.G245D 
c.827C>T p.A276V None None None c.1029G>A p.R343R None 
A030 c.412G>A p.A138T 
c.677G>A p.G226D None None None None None 
A031 c.827C>T p.A276V None None None None None 
A032 c.734G>A p.G245D None None None None None 
A033 None None None None None None 
A034 None c.5983C>T p.P1995S None None None None 
N035 None None None None None None 
N036 None None None None None None 
N037 None None None None None None 
N038 None None None None None None 
N039 None None None None None None 
All low-abundance mutations in this table were validated by repeated deep sequencing. 
Low-abundance mutations written in bold letters are non-synonymous, and those written in small letters are synonymous 
*A029-A034 are H pylori-related gastritis patients without gastric cancer. N035-N039 are individuals without H pylori infection and gastric cancer.  
 
Table 4. Low-abundance TP53 mutations in gastric mucosa of Hupki/AID-Tg mice detected by deep 
sequencing. 
 
Mouse 
number 
Codon 72 
polymorphism* 
AID 
expression** 
Average 
Coverage 
low-abundance TP53 mutation*** 
Nucleotide/Amino acid 
change Coverage 
# of 
Mutant Allele  
1 Arg/Arg + 3082 c.734G>A p.G245D 3056 3 
2 Arg/Arg + 4057 c.734G>A p.G245D 4662 8 
3 Pro/Pro + 4374 
c.734G>A p.G245D 9160 13 
c.844C>T p.R282W 4223 5 
4 Pro/Pro + 6015 c.734G>A p.G245D 11098 12 
5 Pro/Pro + 7570 c.734G>A p.G245D 7694 10 
6 Arg/Pro + 4676 
c.481G>A p.A161T 4551 6 
c.501G>A p.Q167Q 4572 5 
c.734G>A p.G245D 8061 11 
7 Arg/Pro + 8130 None 
8 Arg/Arg - 8853 c.734G>A p.G245D 6170 10 
9 Arg/Arg - 6470 None 
10 Pro/Pro - 5090 None 
11 Pro/Pro - 11036 None 
12 Arg/Pro - 4052 None 
13 Arg/Pro - 10237 None 
All mice were male and sacrificed at 12 months of age. 
*Hupki mouse strain with arginine(Arg)/Arg, proline(Pro)/Pro or Arg/Pro variants at codon 72 of human TP53. A common polymorphism is frequently 
observed at codon 72 in TP53, resulting in either a Pro or an Arg, and the polymorphism at codon 72 affect critical biochemical properties of p53 
protein (Ref. 49) 
**Constitutive AID expression of the stomach was achieved by crossing Hupki mice with AID-Tg mice. 
***Low-abundance somatic mutations accumulated in human TP53 gene sequences in the gastric mucosa of Hupki mice. 
 
 
